The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young women

The objective of this study was to assess the risk of myocardial infarction (MI) associated with the use of new and old combination oral contraceptives (OC). A matched case-control study in 16 centers in Germany, the United Kingdom, France, Austria, and Switzerland explored the association of curren...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Contraception (Stoneham) 1997-09, Vol.56 (3), p.129-140
Hauptverfasser: Lewis, Michael A., Heinemann, Lothar A.J., Spitzer, Walter O., MacRae, Kenneth D., Bruppacher, Rudolf
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 140
container_issue 3
container_start_page 129
container_title Contraception (Stoneham)
container_volume 56
creator Lewis, Michael A.
Heinemann, Lothar A.J.
Spitzer, Walter O.
MacRae, Kenneth D.
Bruppacher, Rudolf
description The objective of this study was to assess the risk of myocardial infarction (MI) associated with the use of new and old combination oral contraceptives (OC). A matched case-control study in 16 centers in Germany, the United Kingdom, France, Austria, and Switzerland explored the association of current use of combination OC with the occurrence of MI. Our subjects were 182 women aged 16–44 years with MI; the controls were 635 women with-out MI (at least one hospital control and one community control per case) matched for 5-year age group and region. The main outcome measures were odds ratios comparing current use of a specific group of OC against current use of other groups or against no current use. The adjusted overall odds ratio (OR; 95% confidence intervals) for MI for second generation OC versus no current use was 2.35 (1.42 to 3.89) and 0.82 (0.29 to 2.31) for third generation OC (low dose ethinyl estradiol, gestodene, and desogestrel). A direct comparison of third generation users with second generation users yielded an OR of 0.28 (0.09 to 0.86). In subgroup analyses, the odds ratio for the UK alone was 1.25 (0.36 to 4.29), while for continental Europe it was 0.10 (0.02 to 0.48). For hospital controls, the risk estimated was 0.98 (0.22 to 4.44), and 0.18 (0.04 to 0.65) for community controls. The independent risk of MI among current smokers adjusted for OC use was 7.21 (4.58 to 11.36). Among users of third generation OC, the OR for current smokers was 3.75 (0.65 to 21.74) and among users of second generation it was 9.50 (2.93 to 30.96). A comparison of OC use in the UK for the time before and after regulatory action was taken in October 1995 shows that the likelihood of a control (last control accrued June 1996) being treated with second generation OC is seven times higher after 1 November 1995 than it was before. Third generation Oc are the first to be associated with no excess risk of MI. A significantly lower risk of MI is found when comparing use of third generation OC with use of second generation OC. There seems to be an impressive amelioration of risk among smokers using newer OC. An impact of regulatory action in the UK was found in the OC use spectrum of controls.
doi_str_mv 10.1016/S0010-7824(97)00118-2
format Article
fullrecord <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_9347202</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010782497001182</els_id><sourcerecordid>9347202</sourcerecordid><originalsourceid>FETCH-LOGICAL-e291t-954080b51ec097a698d7bf27fcd2d819000d199629c35d00a61b5c23ffae2743</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EKtvCI1TygQM9BMZOso65IFS1gFQJqd275bXHrFFir2ynaF-Np8PZripOnGxrvvln_P-EXDL4wICtPz4AMGjEwLv3UlzVBxsa_oKs2CBkAz0bXpLVM_KanOf8CwCE7MUZOZNtJzjwFfmz2SGdM9LoaEx6pCaGkrTBffGPmKkOlpaKRGPmlDCYI6nNXJBOh2h0sr52-eB0MsXHUK_0EOfwk_6OE4ZP9B7zPJZMXYrTUarKhxz0AtfOXGZ7oLXvf9N3qMeyWyb_I_2GvHJ6zPj2dF6Qze3N5vpbc_fj6_frL3cNcslKI_sOBtj2DA1IoddysGLruHDGcjswWU2xTMo1l6btLYBes21veOucRi669oJcPsnu5-2EVu2Tn3Q6qJOFtf7uVNfZ6NHV3xmfnzE-dH0LbcU-P2FYV330mFQ2fvHT-oSmKBu9YqCWaNUxWrXkpqRQx2gVb_8ClcKZYA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young women</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lewis, Michael A. ; Heinemann, Lothar A.J. ; Spitzer, Walter O. ; MacRae, Kenneth D. ; Bruppacher, Rudolf</creator><creatorcontrib>Lewis, Michael A. ; Heinemann, Lothar A.J. ; Spitzer, Walter O. ; MacRae, Kenneth D. ; Bruppacher, Rudolf ; Transnational Research Group on Oral Contraceptives and the Health of Young Women</creatorcontrib><description>The objective of this study was to assess the risk of myocardial infarction (MI) associated with the use of new and old combination oral contraceptives (OC). A matched case-control study in 16 centers in Germany, the United Kingdom, France, Austria, and Switzerland explored the association of current use of combination OC with the occurrence of MI. Our subjects were 182 women aged 16–44 years with MI; the controls were 635 women with-out MI (at least one hospital control and one community control per case) matched for 5-year age group and region. The main outcome measures were odds ratios comparing current use of a specific group of OC against current use of other groups or against no current use. The adjusted overall odds ratio (OR; 95% confidence intervals) for MI for second generation OC versus no current use was 2.35 (1.42 to 3.89) and 0.82 (0.29 to 2.31) for third generation OC (low dose ethinyl estradiol, gestodene, and desogestrel). A direct comparison of third generation users with second generation users yielded an OR of 0.28 (0.09 to 0.86). In subgroup analyses, the odds ratio for the UK alone was 1.25 (0.36 to 4.29), while for continental Europe it was 0.10 (0.02 to 0.48). For hospital controls, the risk estimated was 0.98 (0.22 to 4.44), and 0.18 (0.04 to 0.65) for community controls. The independent risk of MI among current smokers adjusted for OC use was 7.21 (4.58 to 11.36). Among users of third generation OC, the OR for current smokers was 3.75 (0.65 to 21.74) and among users of second generation it was 9.50 (2.93 to 30.96). A comparison of OC use in the UK for the time before and after regulatory action was taken in October 1995 shows that the likelihood of a control (last control accrued June 1996) being treated with second generation OC is seven times higher after 1 November 1995 than it was before. Third generation Oc are the first to be associated with no excess risk of MI. A significantly lower risk of MI is found when comparing use of third generation OC with use of second generation OC. There seems to be an impressive amelioration of risk among smokers using newer OC. An impact of regulatory action in the UK was found in the OC use spectrum of controls.</description><identifier>ISSN: 0010-7824</identifier><identifier>EISSN: 1879-0518</identifier><identifier>DOI: 10.1016/S0010-7824(97)00118-2</identifier><identifier>PMID: 9347202</identifier><identifier>CODEN: CCPTAY</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Austria ; Biological and medical sciences ; Case-Control Studies ; case-control study ; Contraceptives, Oral - adverse effects ; desogestrel ; Desogestrel - administration &amp; dosage ; Drug toxicity and drugs side effects treatment ; epidemiology ; ethinyl estradiol ; Ethinyl Estradiol - administration &amp; dosage ; Female ; France ; Germany ; gestodene ; Humans ; levonorgestrel ; Medical sciences ; myocardial infarction ; Myocardial Infarction - chemically induced ; Myocardial Infarction - epidemiology ; Norpregnenes - administration &amp; dosage ; Odds Ratio ; oral contraceptives ; Pharmacology. Drug treatments ; Progesterone Congeners - administration &amp; dosage ; Risk Factors ; Smoking - adverse effects ; Switzerland ; Toxicity: cardiovascular system ; United Kingdom</subject><ispartof>Contraception (Stoneham), 1997-09, Vol.56 (3), p.129-140</ispartof><rights>1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0010782497001182$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2845303$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9347202$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lewis, Michael A.</creatorcontrib><creatorcontrib>Heinemann, Lothar A.J.</creatorcontrib><creatorcontrib>Spitzer, Walter O.</creatorcontrib><creatorcontrib>MacRae, Kenneth D.</creatorcontrib><creatorcontrib>Bruppacher, Rudolf</creatorcontrib><creatorcontrib>Transnational Research Group on Oral Contraceptives and the Health of Young Women</creatorcontrib><title>The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young women</title><title>Contraception (Stoneham)</title><addtitle>Contraception</addtitle><description>The objective of this study was to assess the risk of myocardial infarction (MI) associated with the use of new and old combination oral contraceptives (OC). A matched case-control study in 16 centers in Germany, the United Kingdom, France, Austria, and Switzerland explored the association of current use of combination OC with the occurrence of MI. Our subjects were 182 women aged 16–44 years with MI; the controls were 635 women with-out MI (at least one hospital control and one community control per case) matched for 5-year age group and region. The main outcome measures were odds ratios comparing current use of a specific group of OC against current use of other groups or against no current use. The adjusted overall odds ratio (OR; 95% confidence intervals) for MI for second generation OC versus no current use was 2.35 (1.42 to 3.89) and 0.82 (0.29 to 2.31) for third generation OC (low dose ethinyl estradiol, gestodene, and desogestrel). A direct comparison of third generation users with second generation users yielded an OR of 0.28 (0.09 to 0.86). In subgroup analyses, the odds ratio for the UK alone was 1.25 (0.36 to 4.29), while for continental Europe it was 0.10 (0.02 to 0.48). For hospital controls, the risk estimated was 0.98 (0.22 to 4.44), and 0.18 (0.04 to 0.65) for community controls. The independent risk of MI among current smokers adjusted for OC use was 7.21 (4.58 to 11.36). Among users of third generation OC, the OR for current smokers was 3.75 (0.65 to 21.74) and among users of second generation it was 9.50 (2.93 to 30.96). A comparison of OC use in the UK for the time before and after regulatory action was taken in October 1995 shows that the likelihood of a control (last control accrued June 1996) being treated with second generation OC is seven times higher after 1 November 1995 than it was before. Third generation Oc are the first to be associated with no excess risk of MI. A significantly lower risk of MI is found when comparing use of third generation OC with use of second generation OC. There seems to be an impressive amelioration of risk among smokers using newer OC. An impact of regulatory action in the UK was found in the OC use spectrum of controls.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Austria</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>case-control study</subject><subject>Contraceptives, Oral - adverse effects</subject><subject>desogestrel</subject><subject>Desogestrel - administration &amp; dosage</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>epidemiology</subject><subject>ethinyl estradiol</subject><subject>Ethinyl Estradiol - administration &amp; dosage</subject><subject>Female</subject><subject>France</subject><subject>Germany</subject><subject>gestodene</subject><subject>Humans</subject><subject>levonorgestrel</subject><subject>Medical sciences</subject><subject>myocardial infarction</subject><subject>Myocardial Infarction - chemically induced</subject><subject>Myocardial Infarction - epidemiology</subject><subject>Norpregnenes - administration &amp; dosage</subject><subject>Odds Ratio</subject><subject>oral contraceptives</subject><subject>Pharmacology. Drug treatments</subject><subject>Progesterone Congeners - administration &amp; dosage</subject><subject>Risk Factors</subject><subject>Smoking - adverse effects</subject><subject>Switzerland</subject><subject>Toxicity: cardiovascular system</subject><subject>United Kingdom</subject><issn>0010-7824</issn><issn>1879-0518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi0EKtvCI1TygQM9BMZOso65IFS1gFQJqd275bXHrFFir2ynaF-Np8PZripOnGxrvvln_P-EXDL4wICtPz4AMGjEwLv3UlzVBxsa_oKs2CBkAz0bXpLVM_KanOf8CwCE7MUZOZNtJzjwFfmz2SGdM9LoaEx6pCaGkrTBffGPmKkOlpaKRGPmlDCYI6nNXJBOh2h0sr52-eB0MsXHUK_0EOfwk_6OE4ZP9B7zPJZMXYrTUarKhxz0AtfOXGZ7oLXvf9N3qMeyWyb_I_2GvHJ6zPj2dF6Qze3N5vpbc_fj6_frL3cNcslKI_sOBtj2DA1IoddysGLruHDGcjswWU2xTMo1l6btLYBes21veOucRi669oJcPsnu5-2EVu2Tn3Q6qJOFtf7uVNfZ6NHV3xmfnzE-dH0LbcU-P2FYV330mFQ2fvHT-oSmKBu9YqCWaNUxWrXkpqRQx2gVb_8ClcKZYA</recordid><startdate>19970901</startdate><enddate>19970901</enddate><creator>Lewis, Michael A.</creator><creator>Heinemann, Lothar A.J.</creator><creator>Spitzer, Walter O.</creator><creator>MacRae, Kenneth D.</creator><creator>Bruppacher, Rudolf</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19970901</creationdate><title>The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young women</title><author>Lewis, Michael A. ; Heinemann, Lothar A.J. ; Spitzer, Walter O. ; MacRae, Kenneth D. ; Bruppacher, Rudolf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e291t-954080b51ec097a698d7bf27fcd2d819000d199629c35d00a61b5c23ffae2743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Austria</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>case-control study</topic><topic>Contraceptives, Oral - adverse effects</topic><topic>desogestrel</topic><topic>Desogestrel - administration &amp; dosage</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>epidemiology</topic><topic>ethinyl estradiol</topic><topic>Ethinyl Estradiol - administration &amp; dosage</topic><topic>Female</topic><topic>France</topic><topic>Germany</topic><topic>gestodene</topic><topic>Humans</topic><topic>levonorgestrel</topic><topic>Medical sciences</topic><topic>myocardial infarction</topic><topic>Myocardial Infarction - chemically induced</topic><topic>Myocardial Infarction - epidemiology</topic><topic>Norpregnenes - administration &amp; dosage</topic><topic>Odds Ratio</topic><topic>oral contraceptives</topic><topic>Pharmacology. Drug treatments</topic><topic>Progesterone Congeners - administration &amp; dosage</topic><topic>Risk Factors</topic><topic>Smoking - adverse effects</topic><topic>Switzerland</topic><topic>Toxicity: cardiovascular system</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lewis, Michael A.</creatorcontrib><creatorcontrib>Heinemann, Lothar A.J.</creatorcontrib><creatorcontrib>Spitzer, Walter O.</creatorcontrib><creatorcontrib>MacRae, Kenneth D.</creatorcontrib><creatorcontrib>Bruppacher, Rudolf</creatorcontrib><creatorcontrib>Transnational Research Group on Oral Contraceptives and the Health of Young Women</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Contraception (Stoneham)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lewis, Michael A.</au><au>Heinemann, Lothar A.J.</au><au>Spitzer, Walter O.</au><au>MacRae, Kenneth D.</au><au>Bruppacher, Rudolf</au><aucorp>Transnational Research Group on Oral Contraceptives and the Health of Young Women</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young women</atitle><jtitle>Contraception (Stoneham)</jtitle><addtitle>Contraception</addtitle><date>1997-09-01</date><risdate>1997</risdate><volume>56</volume><issue>3</issue><spage>129</spage><epage>140</epage><pages>129-140</pages><issn>0010-7824</issn><eissn>1879-0518</eissn><coden>CCPTAY</coden><abstract>The objective of this study was to assess the risk of myocardial infarction (MI) associated with the use of new and old combination oral contraceptives (OC). A matched case-control study in 16 centers in Germany, the United Kingdom, France, Austria, and Switzerland explored the association of current use of combination OC with the occurrence of MI. Our subjects were 182 women aged 16–44 years with MI; the controls were 635 women with-out MI (at least one hospital control and one community control per case) matched for 5-year age group and region. The main outcome measures were odds ratios comparing current use of a specific group of OC against current use of other groups or against no current use. The adjusted overall odds ratio (OR; 95% confidence intervals) for MI for second generation OC versus no current use was 2.35 (1.42 to 3.89) and 0.82 (0.29 to 2.31) for third generation OC (low dose ethinyl estradiol, gestodene, and desogestrel). A direct comparison of third generation users with second generation users yielded an OR of 0.28 (0.09 to 0.86). In subgroup analyses, the odds ratio for the UK alone was 1.25 (0.36 to 4.29), while for continental Europe it was 0.10 (0.02 to 0.48). For hospital controls, the risk estimated was 0.98 (0.22 to 4.44), and 0.18 (0.04 to 0.65) for community controls. The independent risk of MI among current smokers adjusted for OC use was 7.21 (4.58 to 11.36). Among users of third generation OC, the OR for current smokers was 3.75 (0.65 to 21.74) and among users of second generation it was 9.50 (2.93 to 30.96). A comparison of OC use in the UK for the time before and after regulatory action was taken in October 1995 shows that the likelihood of a control (last control accrued June 1996) being treated with second generation OC is seven times higher after 1 November 1995 than it was before. Third generation Oc are the first to be associated with no excess risk of MI. A significantly lower risk of MI is found when comparing use of third generation OC with use of second generation OC. There seems to be an impressive amelioration of risk among smokers using newer OC. An impact of regulatory action in the UK was found in the OC use spectrum of controls.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9347202</pmid><doi>10.1016/S0010-7824(97)00118-2</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0010-7824
ispartof Contraception (Stoneham), 1997-09, Vol.56 (3), p.129-140
issn 0010-7824
1879-0518
language eng
recordid cdi_pubmed_primary_9347202
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adolescent
Adult
Austria
Biological and medical sciences
Case-Control Studies
case-control study
Contraceptives, Oral - adverse effects
desogestrel
Desogestrel - administration & dosage
Drug toxicity and drugs side effects treatment
epidemiology
ethinyl estradiol
Ethinyl Estradiol - administration & dosage
Female
France
Germany
gestodene
Humans
levonorgestrel
Medical sciences
myocardial infarction
Myocardial Infarction - chemically induced
Myocardial Infarction - epidemiology
Norpregnenes - administration & dosage
Odds Ratio
oral contraceptives
Pharmacology. Drug treatments
Progesterone Congeners - administration & dosage
Risk Factors
Smoking - adverse effects
Switzerland
Toxicity: cardiovascular system
United Kingdom
title The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the transnational study on oral contraceptives and the health of young women
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A12%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20oral%20contraceptives%20and%20the%20occurrence%20of%20acute%20myocardial%20infarction%20in%20young%20women:%20Results%20from%20the%20transnational%20study%20on%20oral%20contraceptives%20and%20the%20health%20of%20young%20women&rft.jtitle=Contraception%20(Stoneham)&rft.au=Lewis,%20Michael%20A.&rft.aucorp=Transnational%20Research%20Group%20on%20Oral%20Contraceptives%20and%20the%20Health%20of%20Young%20Women&rft.date=1997-09-01&rft.volume=56&rft.issue=3&rft.spage=129&rft.epage=140&rft.pages=129-140&rft.issn=0010-7824&rft.eissn=1879-0518&rft.coden=CCPTAY&rft_id=info:doi/10.1016/S0010-7824(97)00118-2&rft_dat=%3Cpubmed_pasca%3E9347202%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9347202&rft_els_id=S0010782497001182&rfr_iscdi=true